StockNews.com initiated coverage on shares of RedHill Biopharma (NASDAQ:RDHL – Free Report) in a research note released on Saturday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
RedHill Biopharma Price Performance
RDHL stock opened at $2.66 on Friday. RedHill Biopharma has a 1 year low of $2.47 and a 1 year high of $20.28. The company’s 50-day moving average is $4.37 and its 200-day moving average is $6.51.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in RedHill Biopharma stock. GAMMA Investing LLC purchased a new position in RedHill Biopharma Ltd. (NASDAQ:RDHL – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned approximately 0.40% of RedHill Biopharma at the end of the most recent reporting period. Institutional investors own 7.20% of the company’s stock.
About RedHill Biopharma
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.
See Also
- Five stocks we like better than RedHill Biopharma
- What is the Nikkei 225 index?
- 3 Buyable Stocks With Solid Bottoms Ready to Rebound
- The 3 Best Retail Stocks to Shop for in August
- Advantage+ Shopping: Meta’s Fast Growing $20 Billion AI-Ads Star
- What is the Dogs of the Dow Strategy? Overview and Examples
- Robotaxi News: What Tesla and Lyft Headlines Mean for Shares
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
